Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to -$77000.0.

  • Akebia Therapeutics' Cash from Investing Activities fell 375000.0% to -$77000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$51000.0, marking a year-over-year decrease of 6451.61%. This contributed to the annual value of -$33000.0 for FY2024, which is N/A changed from last year.
  • Per Akebia Therapeutics' latest filing, its Cash from Investing Activities stood at -$77000.0 for Q3 2025, which was down 375000.0% from -$126000.0 recorded in Q2 2025.
  • Akebia Therapeutics' Cash from Investing Activities' 5-year high stood at $20.0 million during Q2 2021, with a 5-year trough of -$126000.0 in Q2 2025.
  • Its 4-year average for Cash from Investing Activities is $4.4 million, with a median of -$2000.0 in 2024.
  • In the last 5 years, Akebia Therapeutics' Cash from Investing Activities soared by 803918.37% in 2021 and then crashed by 375000.0% in 2025.
  • Akebia Therapeutics' Cash from Investing Activities (Quarter) stood at $20.0 million in 2021, then tumbled by 100.57% to -$114000.0 in 2022, then skyrocketed by 98.25% to -$2000.0 in 2024, then crashed by 3750.0% to -$77000.0 in 2025.
  • Its Cash from Investing Activities was -$77000.0 in Q3 2025, compared to -$126000.0 in Q2 2025 and $154000.0 in Q1 2025.